GlassScriptPhysician profile
Edward Weich Liu
NPI 1871587683
$54,690.28
in general payments reported to CMS, 2019-2025
46 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $5,561 · 2021: $2,394 · 2022: $3,908 · 2023: $7,468 · 2024: $14K · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,032 · Food and Beverage: $2,669 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,860.00 |
| Travel and Lodging | $5,032.42 |
| Food and Beverage | $2,669.46 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $50,201.54 | 2019-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $696.47 | 2019-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $532.23 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $513.59 | 2019-2025 | |
| Insmed, INC. | $424.87 | 2019-2025 | Arikayce |
| Shionogi INC | $236.01 | 2020-2024 | Fetroja |
| Janssen Biotech, INC. | $223.61 | 2019-2023 | Tremfya |
| Theratechnologies INC. | $179.77 | 2019-2024 | Egrifta, Trogarzo |
| Astellas Pharma US INC | $157.27 | 2019-2020 | |
| Biomerieux INC | $139.64 | 2021-2022 | |
| Allergan, INC. | $104.85 | 2019-2020 | |
| Dynavax Technologies Corporation | $92.15 | 2019-2021 | |
| Corcept Therapeutics | $88.11 | 2020-2023 | Korlym |
| Melinta Therapeutics, LLC | $78.63 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Mannkind Corporation | $69.80 | 2022-2023 | Afrezza |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.